Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest- ever deal to bolster its positions in immunology and rare diseases. Alexion shareholders would receive $60 in cash and about $115 worth of equity per share.

0
0
  •  
  •  
  •  
  •  
  •  
  •  
  •  

admin

WWW.ALPHATECH.NEWS, Breaking Fintech & Cryptocurrency News

0 0 vote
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments